-
Ivonescimab-Chemotherapy Combo Shows Promise as Post-TKI Option in EGFR-Mutant NSCLC
Dr. Jonathan W. Goldman reported that ivonescimab plus chemotherapy yielded a consistent PFS benefit across subgroups.
More News from #WCLC25
-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
Dr. Mariano Provencio said the results could potentially define a standard adjuvant treatment for patients with resectable ES-NSCLC; however, longer-term observation is needed.
-
COMPEL Data Show Osimertinib Plus Chemo Beats Chemo Alone for EGFRm NSCLC Following Progression
While ultimately underpowered, Dr. Giulia Pasello said combination therapy demonstrated an improvement in median PFS compared to chemotherapy alone.